Look, you’re going to experience nausea and potentially vominating in the early phase but it will end and you can walk patients through and that’s working. So we feel really good about the overall tolerability and persistence in general here. And then, as she said, you got a handful of patients who are discontinuing for personal reasons, which are a sense unrelated to the drug of the problem and that happens in any disease area.
Joseph Stringer: Great. Thanks for taking our question.
Operator: Our next question comes from Jeff Hung with Morgan Stanley. Your line is now open.
Michael Riad: Hi. This is Michael Riad on for Jeff Hung. Thank you for taking our questions. First, regarding the 22% of prescribers that weren’t called on by a territory manager, were they in any particular region of the country? And what is Rhythm learning from these interactions? And how could that be applied to bring in additional prescribers? Thanks.
Jennifer Chien: Yes. We’re actually very happy seeing this percentage just in terms of patients that are coming through not directly through the efforts of our territory manager. I think it speaks to a couple of different things in terms of our more broader based efforts and our personal promotion efforts that get to a broader set of those patients out there as well as physicians, which may be why there could be more of a skew in terms of this physician population skewing more towards like primary care physicians. But these patients are in the hands of so many different physicians as they go through their journey. So we have to be both targeted in our field efforts but also broad based in terms of outreach through other supportive mechanisms.
I think that would fall into that category, of course, also relate to our presence at conferences, our ongoing dialogues and relationship with the BBS foundation and such. But I would say that, if there’s a motivated physician who is going to prescribed. This is a drug that can be prescribed and managed by a very different specialty background. So we continue our education efforts with each physician who has been interested, who has put in a prescription.
Michael Riad: Okay, thanks. And maybe a second follow-up for the Phase 3 and hypoglymic obesity. What factors would push enrollment closer to the 12 month mark. Given patients are — diagnosed patients are well known, is it more the logistics of getting sites up and running? And finally, what would you see as the biggest hurdle for this study? Thanks so much.
David Meeker: Yes. It is the logistics that I think we talked about on some of the earlier calls. The trial network or infrastructure globally in the U.S. for sure as well is challenged coming out of COVID. And so a number of these sites have personnel challenges, in terms of study nurses getting things through for pure logistics as you noted. So that is the issue. The patient demand is there. Patients are — every site that we’ve talked to who signed up to be part of this trial are enthusiastic and has a surprising number of patients relative to my experience in other trials in these areas. So that would be a — your question was anything that could make it go faster so that we can get all set up, we’ll highlight to sites as we have already that we expect enrollment to be competitive and that could be a useful dynamic as sites have a number of patients who may want to participate and they’ll be hopefully push to get them in, we are limited only by maybe their study nurse’s ability to do a process, that’ll be the balance.
